SG11201908531WA - Combination therapies for the treatment of breast cancer - Google Patents

Combination therapies for the treatment of breast cancer

Info

Publication number
SG11201908531WA
SG11201908531WA SG11201908531WA SG11201908531WA SG 11201908531W A SG11201908531W A SG 11201908531WA SG 11201908531W A SG11201908531W A SG 11201908531WA SG 11201908531W A SG11201908531W A SG 11201908531WA
Authority
SG
Singapore
Prior art keywords
international
massachusetts
rule
pct
applicant
Prior art date
Application number
Inventor
Craig D Karr
Manav Korpal
Nathalie Rioux
Peter Gerard Smith
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201908531WA publication Critical patent/SG11201908531WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT o mono VIII °nolo mo IIIII Ho oimIE (10) International Publication Number WO 2018/170447 Al (51) International Patent Classification: A61K 45/06 (2006.01) A61K 31/519 (2006.01) A61K 31/445 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/022961 Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) W O 20 18/ 17 0 447 Al (22) International Filing Date: Published: 16 March 2018 (16.03.2018) — with international search report (Art. 21(3)) (25) Filing Language: English with sequence listing part of description (Rule 5.2(a)) (26) Publication Language: English (30) Priority Data: 62/472,345 16 March 2017 (16.03.2017) US (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. [JP/JP]; 6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo, 112-8088 (JP). (72) Inventors; and (71) Applicants (for US only): KARR, Craig D. [US/US]; 550 Liberty Street, Braintree, Massachusetts 02184 (US). KO- RPAL, Manav [CA/US]; 18 Myrtle Street, Winchester, Massachusetts 01890 (US). RIOUX, Nathalie [CA/US]; 5 Highview Road, Woburn, Massachusetts 01801 (US). SMITH, Peter Gerard [GB/US]; 173A Franklin Street, Arlington, Massachusetts 02474 (US). (74) Agent: WALTERS, Todd R. et al.; Buchanan Inger- soll & Rooney PC, P.O. Box 1404, Alexandria, Virginia 22313-1404 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER (57) : Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER- alpha inhibitor and a CDK 4/6 inhibitor.
SG11201908531W 2017-03-16 2018-03-16 Combination therapies for the treatment of breast cancer SG11201908531WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472345P 2017-03-16 2017-03-16
PCT/US2018/022961 WO2018170447A1 (en) 2017-03-16 2018-03-16 Combination therapies for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
SG11201908531WA true SG11201908531WA (en) 2019-10-30

Family

ID=61874039

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908531W SG11201908531WA (en) 2017-03-16 2018-03-16 Combination therapies for the treatment of breast cancer

Country Status (14)

Country Link
US (1) US11083722B2 (en)
EP (2) EP4218820A3 (en)
JP (1) JP7219224B2 (en)
KR (1) KR102517650B1 (en)
CN (1) CN110636862A (en)
AU (1) AU2018234903B2 (en)
BR (1) BR112019019261A2 (en)
CA (1) CA3056701A1 (en)
IL (1) IL269357A (en)
MA (1) MA47776A (en)
MX (1) MX2019010981A (en)
RU (1) RU2764724C2 (en)
SG (1) SG11201908531WA (en)
WO (1) WO2018170447A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747399C2 (en) * 2016-11-28 2021-05-04 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Indazole derivative salts and their crystals
AU2019205821A1 (en) 2018-01-08 2020-07-09 G1 Therapeutics, Inc. G1T38 superior dosage regimes
US20230404987A1 (en) * 2020-11-06 2023-12-21 Eisai R&D Management Co., Ltd. Method of treating breast cancer
CN113018357A (en) * 2021-02-08 2021-06-25 湖南农业大学 Application of tea polyphenol and palbociclib combination in preparation of preparation for treating breast cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (en) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmaceutical preparation for the treatment of tumor diseases
KR100825530B1 (en) 2000-01-18 2008-04-25 아벤티스 파마슈티칼스 인크. Ethanol solvate of --cis-2-2-chlorophenyl-5,7-dihydroxy-8[4?-3?-hydroxy-1-methylpiperidinyl]-4?-1-benzopyran-4-one
SI1259507T1 (en) 2000-01-18 2005-02-28 Aventis Pharmaceuticals Inc. Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl)-4h-1-benzopyran-4-one hydrochloride
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
CN101001857B (en) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
PL1651612T3 (en) 2003-07-22 2012-09-28 Astex Therapeutics Ltd 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
MX2007008781A (en) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Pharmaceutical compounds.
JP5475234B2 (en) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド Pharmaceutical compounds
RU2007131101A (en) 2005-01-21 2009-02-27 Астекс Терапьютикс Лимитед (Gb) COMBINATIONS OF PYRAZOLIC KINASE INHIBITORS AND OTHER MEDICINES AGAINST MALIGNANT NEW FORMATIONS
JP2008255008A (en) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ Synoviocyte proliferation inhibitor
US7776832B2 (en) * 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
JO3235B1 (en) 2006-05-26 2018-03-08 Astex Therapeutics Ltd Pyrrolopyrimidine compounds and their uses
JP2009542608A (en) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド Pharmaceutical combination
JP2009543770A (en) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Combinations of pyrazole derivatives for the inhibition of CDK and GSK
JP2009543768A (en) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Pharmaceutical combination
WO2008009954A1 (en) 2006-07-21 2008-01-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
PT2331547E (en) 2008-08-22 2014-10-29 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
UY33226A (en) 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPUTERS DEUTERATED AS INHIBITORS OF THE CDK4 / 6
ES2689177T3 (en) 2010-04-13 2018-11-08 Novartis Ag Combination comprising a cyclin dependent kinase 4 inhibitor or cyclin dependent kinase (CDK4 / 6) and an mTOR inhibitor for treating cancer
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
MX367795B (en) 2010-10-25 2019-09-06 G1 Therapeutics Inc Cdk inhibitors.
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
PT2688887E (en) 2011-03-23 2015-07-06 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9408847B2 (en) 2012-11-28 2016-08-09 Novartis Ag Combination therapy
CN105473140B (en) 2013-03-15 2018-04-10 G1治疗公司 To the instantaneous protection of normal cell during chemotherapy
HRP20211879T1 (en) 2013-08-14 2022-03-04 Novartis Ag Combination therapy for the treatment of cancer
JP2017507964A (en) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Therapeutic combinations using estrogen receptor modulators
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (en) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 The preparation method of Bo Maxini
WO2016126889A1 (en) 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
IL255148B2 (en) * 2015-04-29 2023-04-01 Radius Pharmaceuticals Inc Rad 1901 for use in a method of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant and/or mutant estrogen receptor alpha-positive cancer
DK3302471T3 (en) 2015-05-29 2021-11-15 Eisai R&D Man Co Ltd TETRA-SUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Also Published As

Publication number Publication date
WO2018170447A1 (en) 2018-09-20
EP4218820A2 (en) 2023-08-02
EP3595725A1 (en) 2020-01-22
BR112019019261A2 (en) 2020-06-16
AU2018234903A1 (en) 2019-10-10
RU2019132893A (en) 2021-04-16
KR102517650B1 (en) 2023-04-05
JP2020510075A (en) 2020-04-02
EP4218820A3 (en) 2023-09-20
AU2018234903B2 (en) 2024-02-08
US20210113537A1 (en) 2021-04-22
CN110636862A (en) 2019-12-31
RU2764724C2 (en) 2022-01-19
EP3595725B1 (en) 2023-05-03
IL269357A (en) 2019-11-28
CA3056701A1 (en) 2018-09-20
US11083722B2 (en) 2021-08-10
MA47776A (en) 2020-01-22
RU2019132893A3 (en) 2021-06-24
JP7219224B2 (en) 2023-02-07
KR20190125448A (en) 2019-11-06
MX2019010981A (en) 2020-09-07

Similar Documents

Publication Publication Date Title
SG11201908531WA (en) Combination therapies for the treatment of breast cancer
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201907870VA (en) Compositions and methods for inhibition of lineage specific proteins
SG11201811457QA (en) Methods and devices for valve clip excision
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201910198UA (en) Multibiotic agents and methods of using the same
SG11201808231VA (en) Delivery system
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201903786UA (en) Farnesyltransferase inhibitors for use in methods of treating cancer
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase
SG11201901505SA (en) I domain chimeric antigen receptor specific to icam-1
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases